ID
11730
Description
The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual antiplatelet treatment in patients with an index event (MI) at high risk for new ischaemic cardiovascular events.
Keywords
Versions (2)
- 7/28/15 7/28/15 -
- 11/21/15 11/21/15 -
Uploaded on
July 28, 2015
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0 Legacy
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Criteria: RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome
Eligibility criteria
- StudyEvent: ODM
Description
Exclusion criteria
Description
Long term treatment with any other oral anticoagulant
Data type
boolean
Alias
- UMLS CUI-1
- C0354604
Description
Severe/disabling stroke within last 6 months
Data type
boolean
Alias
- UMLS CUI-1
- C0038454
Description
Conditions associated with increased bleeding risk
Data type
boolean
Alias
- UMLS CUI-1
- C3251812
Description
Anaemia
Data type
boolean
Alias
- UMLS CUI-1
- C0002871
Description
Thrombocytopenia
Data type
boolean
Alias
- UMLS CUI-1
- C0040034
Description
Severe renal impairment
Data type
boolean
Alias
- UMLS CUI-1
- C0035078
Description
Liver disease
Data type
boolean
Alias
- UMLS CUI-1
- C0085605
Description
Positive pregnancy test
Data type
boolean
Alias
- UMLS CUI-1
- C0549206
Similar models
Eligibility criteria
- StudyEvent: ODM